0

Journal Articles

in Schizophrenia
 1-20 of 309 Articles
Original Article |  May 08, 2013 ONLINE FIRST
Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside:  A Randomized, Double-blind, Placebo-Controlled Trial
Jaime E. C. Hallak, MD, PhD; Joao Paulo Maia-de-Oliveira, MD; Joao Abrao, MD, PhD; et al.
JAMA Psychiatry. 2013;():1-9. doi:10.1001/jamapsychiatry.2013.1292.
Editorial |  May 08, 2013 ONLINE FIRST
Nitric Oxide and Symptom Reduction in Schizophrenia
Joseph T. Coyle, MD
JAMA Psychiatry. 2013;():1-2. doi:10.1001/jamapsychiatry.2013.210.
Original Article |  May 01, 2013
Neuroimaging Evidence for the Deficit Subtype of Schizophrenia
Aristotle N. Voineskos, MD, PhD, FRCPC; George Foussias, MD, MSc, FRCPC; Jason Lerch, PhD; et al.
JAMA Psychiatry. 2013;70(5):472-480. doi:10.1001/jamapsychiatry.2013.786.
INCLUDES: , Supplemental Content
Original Article |  May 01, 2013
Randomized Multicenter Investigation of Folate Plus Vitamin B12 Supplementation in Schizophrenia
Joshua L. Roffman, MD, MMSc; J. Steven Lamberti, MD; Eric Achtyes, MD, MS; et al.
JAMA Psychiatry. 2013;70(5):481-489. doi:10.1001/jamapsychiatry.2013.900.
INCLUDES: , Supplemental Content
Original Article |  April 03, 2013 ONLINE FIRST
Support for the N -Methyl-D-Aspartate Receptor Hypofunction Hypothesis of Schizophrenia From Exome Sequencing in Multiplex Families
Andrew E. Timms, PhD; Michael O. Dorschner, PhD; Jeremy Wechsler, MS; et al.
JAMA Psychiatry. 2013;():1-9. doi:10.1001/jamapsychiatry.2013.1195.
INCLUDES: , Supplemental Content
Original Article |  April 01, 2013
Globally and Locally Reduced MRI Gray Matter Volumes in Neuroleptic-Naive Men With Schizotypal Personality Disorder:  Association With Negative Symptoms
Takeshi Asami, MD, PhD; Thomas J. Whitford, PhD; Sylvain Bouix, PhD; et al.
JAMA Psychiatry. 2013;70(4):361-372. doi:10.1001/jamapsychiatry.2013.665.
INCLUDES: , Supplemental Content
Original Article |  April 01, 2013
Full Spectrum of Psychiatric Disorders Related to Foreign Migration:  A Danish Population-Based Cohort Study
Elizabeth Cantor-Graae, PhD; Carsten B. Pedersen, DMSc
JAMA Psychiatry. 2013;70(4):427-435. doi:10.1001/jamapsychiatry.2013.441.
INCLUDES: , Supplemental Content
Original Article |  March 01, 2013
Implication of a Rare Deletion at Distal 16p11.2 in Schizophrenia
Saurav Guha, PhD; Elliott Rees, MRes; Ariel Darvasi, PhD; et al.
JAMA Psychiatry. 2013;70(3):253-260. doi:10.1001/2013.jamapsychiatry.71.
INCLUDES: , Supplemental Content
Original Article |  March 01, 2013
Increased Prevalence of Diverse N -Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of Schizophrenia:  Specific Relevance of IgG NR1a Antibodies for Distinction From N -Methyl-D-Aspartate Glutamate Receptor Encephalitis
Johann Steiner, MD; Martin Walter, MD; Wenzel Glanz, MD; et al.
JAMA Psychiatry. 2013;70(3):271-278. doi:10.1001/2013.jamapsychiatry.86.
INCLUDES: , Supplemental Content
Original Article |  January 01, 2013
Thalamocortical Disconnection in the Orbitofrontal Region Associated With Cortical Thinning in Schizophrenia
Manabu Kubota, MD; Jun Miyata, MD, PhD; Akihiko Sasamoto, MD; et al.
JAMA Psychiatry. 2013;70(1):12-21. doi:10.1001/archgenpsychiatry.2012.1023.
INCLUDES: , Supplemental Content
Original Article |  January 01, 2013
Fecundity of Patients With Schizophrenia, Autism, Bipolar Disorder, Depression, Anorexia Nervosa, or Substance Abuse vs Their Unaffected Siblings
Robert A. Power, BSc; Simon Kyaga, MD; Rudolf Uher, MD, PhD, MRCPsych; et al.
JAMA Psychiatry. 2013;70(1):22-30. doi:10.1001/jamapsychiatry.2013.268.
Original Article |  December 01, 2012
From Perception to Functional Outcome in Schizophrenia:  Modeling the Role of Ability and Motivation
Michael F. Green, PhD; Gerhard Hellemann, PhD; William P. Horan, PhD; et al.
Arch Gen Psychiatry. 2012;69(12):1216-1224. doi:10.1001/archgenpsychiatry.2012.652.
Original Article |  December 01, 2012
A System-Level Transcriptomic Analysis of Schizophrenia Using Postmortem Brain Tissue Samples
Panos Roussos, MD, PhD; Pavel Katsel, PhD; Kenneth L. Davis, MD; et al.
Arch Gen Psychiatry. 2012;69(12):1205-1213. doi:10.1001/archgenpsychiatry.2012.704.
INCLUDES: , Supplemental Content
Original Article |  December 01, 2012
Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia
Mette Odegaard Nielsen, MD, PhD; Egill Rostrup, MD, DMSc; Sanne Wulff, MD; et al.
Arch Gen Psychiatry. 2012;69(12):1195-1204. doi:10.1001/archgenpsychiatry.2012.847.
INCLUDES: , Supplemental Content
Original Article |  November 01, 2012 FREE
Family History of Schizophrenia and Bipolar Disorder as Risk Factors for Autism
Patrick F. Sullivan, MD, FRANZCP; Cecilia Magnusson, MD, PhD; Abraham Reichenberg, PhD; et al.
Arch Gen Psychiatry. 2012;69(11):1099-1103. doi:10.1001/archgenpsychiatry.2012.730.
Original Article |  September 01, 2012
Delayed White Matter Growth Trajectory in Young Nonpsychotic Siblings of Patients With Childhood-Onset Schizophrenia
Nitin Gogtay, MD; Xue Hua, PhD; Reva Stidd, BS; et al.
Arch Gen Psychiatry. 2012;69(9):875-884. doi:10.1001/archgenpsychiatry.2011.2084.
INCLUDES: , Supplemental Content
Original Article |  September 01, 2012
Influence of ZNF804a on Brain Structure Volumes and Symptom Severity in Individuals With Schizophrenia
Thomas H. Wassink, MD; Eric A. Epping, MD, PhD; Danielle Rudd, BA; et al.
Arch Gen Psychiatry. 2012;69(9):885-892. doi:10.1001/archgenpsychiatry.2011.2116.
Original Article |  September 01, 2012
Failure of Neural Responses to Safety Cues in Schizophrenia
Daphne J. Holt, MD, PhD; Garth Coombs, BS; Mohamed A. Zeidan, BS; et al.
Arch Gen Psychiatry. 2012;69(9):893-903. doi:10.1001/archgenpsychiatry.2011.2310.
INCLUDES: , Supplemental Content
Original Article |  August 01, 2012
Reduced Natural Oscillatory Frequency of Frontal Thalamocortical Circuits in Schizophrenia
Fabio Ferrarelli, MD, PhD; Simone Sarasso, PhD; Yelena Guller, BS; et al.
Arch Gen Psychiatry. 2012;69(8):766-774. doi:10.1001/archgenpsychiatry.2012.147.
INCLUDES: , Supplemental Content
Meta-analysis |  August 01, 2012
The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment:  Meta-analysis of Imaging Studies
Oliver D. Howes, BM, BCh, MA, MRCPsych, PhD, DM; Joseph Kambeitz, MD; Euitae Kim, MD, PhD; et al.
Arch Gen Psychiatry. 2012;69(8):776-786. doi:10.1001/archgenpsychiatry.2012.169.
INCLUDES: , Supplemental Content

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA
Lab Reports  |  May 01, 2013
Signal of Schizophrenia Risk
Tracy Hampton, PhD
JAMA
Lab Reports  |  March 6, 2013
Schizophrenia–Heart Disease Link
Tracy Hampton, PhD
JAMA Ophthalmology
Ophthalmic Images  |  Nov 2012
Chlorpromazine-Induced Corneal Toxicity
Victor Koh, MBBS; Wei-Boon Khor, MRCS(Ed); Li Lim, FRCS(Ed)
JAMA
Medical News and Perspectives  |  August 15, 2012
Evidence Suggests Complex Links Between Violence and Schizophrenia
Bridget M. Kuehn
© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems